Key Highlights

  • Alvotech's first-half 2026 product and service Revenue fell about 48.3% year over year to about $105.9 million, tied to a temporary manufacturing-improvement program.
  • Manufacturing returned to normal levels by late in the second quarter, according to management.
  • The company reaffirmed its full-year 2026 guidance of about $650 million to $700 million in total revenue.
  • Alvotech resubmitted FDA applications for two biosimilars, with decisions anticipated in the fourth quarter of 2026.

Alvotech (NASDAQ:ALVO), a developer and manufacturer of biosimilar medicines, reported a sharp decline in first-half revenue in 2026 as a manufacturing-improvement program temporarily disrupted output, even as it reaffirmed its full-year guidance and advanced its regulatory pipeline.

Alvotech develops, manufactures and commercializes biosimilars, lower-cost versions of expensive biologic medicines, including Biosimilars of Humira, Stelara, Simponi, Eylea and Prolia/Xgeva, partnering with companies that market them. Its results depend on its product revenue, its Manufacturing output and reliability, and its regulatory approvals and pipeline.

Latest Developments

In its first-half 2026 results, Alvotech reported product and service revenue of about $105.9 million, down about 48.3% year over year, which management attributed to a manufacturing-improvement program that temporarily affected output and product availability, with manufacturing returning to normal levels by late in the second quarter. Total adjusted revenue was about $211.9 million, down about 30.8%, gross Margin was about 54%, and adjusted EBITDA was about $46.9 million; it held about $142.8 million in cash.

The company reaffirmed its full-year 2026 guidance of total revenues of about $650 million to $700 million and adjusted EBITDA of about $180 million to $220 million, implying a significant second-half ramp. It resubmitted FDA applications for two biosimilars, a Simponi biosimilar and an Eylea biosimilar, with decisions anticipated in the fourth quarter of 2026.

Financial and Business Position

Alvotech's sharp first-half revenue decline reflects a temporary manufacturing disruption, now resolved, rather than a loss of demand, and its reaffirmed full-year guidance implies a substantial second-half recovery, though that recovery must materialize. The considerations for investors are the execution of the second-half manufacturing and revenue ramp, the outcomes of its pending FDA decisions, the competitive and pricing dynamics of biosimilars, and its cash position.

Stock-Market Context

In its latest close, ALVO stock rose 0.96%. That gain lines up with the market crediting management's explanation that the revenue decline stemmed from a resolved manufacturing issue rather than any weakness in demand, alongside the reaffirmed full-year guidance.

What Investors Should Watch

Investors may focus on product revenue and the second-half manufacturing and revenue ramp, progress against reaffirmed full-year guidance, the FDA decisions on its pending biosimilars expected in the fourth quarter of 2026, margins, and the cash position. Evidence that manufacturing has normalized and revenue is ramping toward guidance would do the most to sustain the recent gain.

The Bottom Line

In its latest close, ALVO stock rose 0.96%, a gain consistent with growing confidence that the first-half revenue decline was a temporary, now-resolved manufacturing issue rather than a Demand problem. The decisive factors ahead are whether the normalized manufacturing delivers the second-half ramp toward reaffirmed guidance and whether the pending FDA decisions go favorably.